Table 5.
Clinical Characteristics of Quiescent UC Patients with and without Frequent to Constant Abdominal Pain. Patients were defined as having quiescent disease based on the treating physician’s global assessment. Key clinical characteristics were compared among the quiescent groups without pain, those with a SPS=5–6 and those with a SPS≤4
| Variable | Inactive UC without pain (n=201) |
Inactive UC with SPS = 5–6 (n=92) |
Inactive UC with SPS ≤ 4 (n=33) |
p value |
|---|---|---|---|---|
| Age (years) | 45.9 ± 0.5 | 42.0 ± 1.3 | 40.4 ± 2.0* | <0.05 |
| Gender (f(%)/m(%)) | 78(38.8)/123(61.2) | 55(60.0)/37(40.0) | 21(63.6)/12(36.3) | <0.001# |
| Disease Duration (years) | 10.3 ± 0.3 | 9.5 ± 0.6 | 9.6 ± 1.0 | NS |
| Disease Distribution Proctitis Left-sided Pan-Colitis |
8 (3.9%) 70 (34.9%) 123 (61.2%) |
9 (9.8%) 25 (27.2%) 58 (63.0%) |
4 (12.1%) 7 (21.2%) 22 (66.6%) |
<0.05# NS NS |
| CRP (mg/dL) | 0.5 ± 0.4 | 1.14 ± 0.7 | 0.7 ± 0.5 | NS |
| ESR (mm/hr) | 16.3 ± 1.4 | 19.3 ± 1.4 | 25.4 ± 1.6* | <0.05 |
| Coexisting Diagnosis of an Affective Spectrum Disorder |
37 (18.4%) | 11 (12.0%) | 11 (33.3%) | <0.05# |
| Coexisting Diagnosis of IBS | 17 (8.5%) | 18 (19.8%) | 11 (33.3%) | <0.001# |
| Coexisting Diagnosis of a Chronic Pain Syndrome |
44 (21.9%) | 30 (32.6%) | 14 (42.2%) | <0.05# |
| Use of Anti-Depressant Medication |
23 (11.4%) | 17 (18.7%) | 9 (27.2%) | 0.08 |
| Use of Opiate | 2 (1.0%) | 3 (3.3%) | 1 (3.3%) | NS |
| Use of NSAID | 17 (8.5%) | 3 (3.3%) | 5 (15.1%) | NS |
| Use of 5-ASA Therapy | 154 (76.6%) | 77 (83.7%) | 25 (75.8%) | NS |
| Use of Immunomodulator Therapy |
63 (31.3%) | 20 (21.7%) | 9 (27.3%) | NS |
| Use of Biologic Therapy | 40 (19.9%) | 15 (16.3%) | 2 (6.1%) | NS |
*
=p<0.05 compared to control (one-way ANOVA, Bonferroni post-test);
#
=chi-square test).